CN111995676A - Monoclonal antibody aiming at non-RBD (radial basis function) region of new coronavirus spike protein and application thereof - Google Patents
Monoclonal antibody aiming at non-RBD (radial basis function) region of new coronavirus spike protein and application thereof Download PDFInfo
- Publication number
- CN111995676A CN111995676A CN202010926531.9A CN202010926531A CN111995676A CN 111995676 A CN111995676 A CN 111995676A CN 202010926531 A CN202010926531 A CN 202010926531A CN 111995676 A CN111995676 A CN 111995676A
- Authority
- CN
- China
- Prior art keywords
- monoclonal antibody
- protein
- seq
- rbd
- region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010061994 Coronavirus Spike Glycoprotein Proteins 0.000 title claims abstract description 8
- 241000711573 Coronaviridae Species 0.000 claims abstract description 42
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 33
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 22
- 238000000034 method Methods 0.000 claims abstract description 21
- 230000008569 process Effects 0.000 claims abstract description 16
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims abstract description 12
- 238000001514 detection method Methods 0.000 claims abstract description 10
- 206010035664 Pneumonia Diseases 0.000 claims abstract description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 10
- 102000039446 nucleic acids Human genes 0.000 claims description 10
- 150000007523 nucleic acids Chemical class 0.000 claims description 10
- 239000013604 expression vector Substances 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
- 230000036046 immunoreaction Effects 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 241001678559 COVID-19 virus Species 0.000 abstract description 23
- 241000700605 Viruses Species 0.000 abstract description 22
- 231100000419 toxicity Toxicity 0.000 abstract description 5
- 230000001988 toxicity Effects 0.000 abstract description 5
- 239000000243 solution Substances 0.000 description 60
- 102100031673 Corneodesmosin Human genes 0.000 description 49
- 101710139375 Corneodesmosin Proteins 0.000 description 49
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 17
- 238000002835 absorbance Methods 0.000 description 16
- 229940098773 bovine serum albumin Drugs 0.000 description 16
- 238000005406 washing Methods 0.000 description 16
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 14
- 238000002965 ELISA Methods 0.000 description 13
- 238000002823 phage display Methods 0.000 description 13
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 12
- 102000004190 Enzymes Human genes 0.000 description 11
- 108090000790 Enzymes Proteins 0.000 description 11
- 241000588724 Escherichia coli Species 0.000 description 10
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 10
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 10
- 239000000427 antigen Substances 0.000 description 10
- 102000036639 antigens Human genes 0.000 description 10
- 108091007433 antigens Proteins 0.000 description 10
- 238000011161 development Methods 0.000 description 10
- 239000000758 substrate Substances 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- WNZOCXUOGVYYBJ-CDMKHQONSA-N Gly-Phe-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CN)O WNZOCXUOGVYYBJ-CDMKHQONSA-N 0.000 description 6
- CUMXHKAOHNWRFQ-BZSNNMDCSA-N Phe-Asp-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=CC=C1 CUMXHKAOHNWRFQ-BZSNNMDCSA-N 0.000 description 6
- MCIXMYKSPQUMJG-SRVKXCTJSA-N Phe-Ser-Ser Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O MCIXMYKSPQUMJG-SRVKXCTJSA-N 0.000 description 6
- 108010086434 alanyl-seryl-glycine Proteins 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 230000001188 anti-phage Effects 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 235000020183 skimmed milk Nutrition 0.000 description 6
- BUDNAJYVCUHLSV-ZLUOBGJFSA-N Ala-Asp-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O BUDNAJYVCUHLSV-ZLUOBGJFSA-N 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 229920001213 Polysorbate 20 Polymers 0.000 description 5
- 229940096437 Protein S Drugs 0.000 description 5
- 101710198474 Spike protein Proteins 0.000 description 5
- 229960000723 ampicillin Drugs 0.000 description 5
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 238000004091 panning Methods 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 5
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- SDZRIBWEVVRDQI-CIUDSAMLSA-N Ala-Lys-Asp Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(O)=O SDZRIBWEVVRDQI-CIUDSAMLSA-N 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 229930027917 kanamycin Natural products 0.000 description 4
- 229960000318 kanamycin Drugs 0.000 description 4
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 4
- 229930182823 kanamycin A Natural products 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000011148 porous material Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 108010003137 tyrosyltyrosine Proteins 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- YYSWCHMLFJLLBJ-ZLUOBGJFSA-N Ala-Ala-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O YYSWCHMLFJLLBJ-ZLUOBGJFSA-N 0.000 description 3
- AWNAEZICPNGAJK-FXQIFTODSA-N Ala-Met-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(O)=O AWNAEZICPNGAJK-FXQIFTODSA-N 0.000 description 3
- ARHJJAAWNWOACN-FXQIFTODSA-N Ala-Ser-Val Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O ARHJJAAWNWOACN-FXQIFTODSA-N 0.000 description 3
- CREYEAPXISDKSB-FQPOAREZSA-N Ala-Thr-Tyr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O CREYEAPXISDKSB-FQPOAREZSA-N 0.000 description 3
- 102100035765 Angiotensin-converting enzyme 2 Human genes 0.000 description 3
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 description 3
- VKKYFICVTYKFIO-CIUDSAMLSA-N Arg-Ala-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCN=C(N)N VKKYFICVTYKFIO-CIUDSAMLSA-N 0.000 description 3
- AOHKLEBWKMKITA-IHRRRGAJSA-N Arg-Phe-Ser Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N AOHKLEBWKMKITA-IHRRRGAJSA-N 0.000 description 3
- MKJBPDLENBUHQU-CIUDSAMLSA-N Asn-Ser-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O MKJBPDLENBUHQU-CIUDSAMLSA-N 0.000 description 3
- UGXYFDQFLVCDFC-CIUDSAMLSA-N Asn-Ser-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O UGXYFDQFLVCDFC-CIUDSAMLSA-N 0.000 description 3
- JBDLMLZNDRLDIX-HJGDQZAQSA-N Asn-Thr-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O JBDLMLZNDRLDIX-HJGDQZAQSA-N 0.000 description 3
- XYBJLTKSGFBLCS-QXEWZRGKSA-N Asp-Arg-Val Chemical compound NC(N)=NCCC[C@@H](C(=O)N[C@@H](C(C)C)C(O)=O)NC(=O)[C@@H](N)CC(O)=O XYBJLTKSGFBLCS-QXEWZRGKSA-N 0.000 description 3
- QNFRBNZGVVKBNJ-PEFMBERDSA-N Asp-Ile-Gln Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)O)N QNFRBNZGVVKBNJ-PEFMBERDSA-N 0.000 description 3
- MNQMTYSEKZHIDF-GCJQMDKQSA-N Asp-Thr-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O MNQMTYSEKZHIDF-GCJQMDKQSA-N 0.000 description 3
- SZQCDCKIGWQAQN-FXQIFTODSA-N Cys-Arg-Ala Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(O)=O SZQCDCKIGWQAQN-FXQIFTODSA-N 0.000 description 3
- 238000012286 ELISA Assay Methods 0.000 description 3
- OYTPNWYZORARHL-XHNCKOQMSA-N Gln-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCC(=O)N)N OYTPNWYZORARHL-XHNCKOQMSA-N 0.000 description 3
- LPYPANUXJGFMGV-FXQIFTODSA-N Gln-Gln-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)N)N LPYPANUXJGFMGV-FXQIFTODSA-N 0.000 description 3
- JXFLPKSDLDEOQK-JHEQGTHGSA-N Gln-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CCC(N)=O JXFLPKSDLDEOQK-JHEQGTHGSA-N 0.000 description 3
- FQCILXROGNOZON-YUMQZZPRSA-N Gln-Pro-Gly Chemical compound NC(=O)CC[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O FQCILXROGNOZON-YUMQZZPRSA-N 0.000 description 3
- OSCLNNWLKKIQJM-WDSKDSINSA-N Gln-Ser-Gly Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(O)=O OSCLNNWLKKIQJM-WDSKDSINSA-N 0.000 description 3
- SXFPZRRVWSUYII-KBIXCLLPSA-N Gln-Ser-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(=O)N)N SXFPZRRVWSUYII-KBIXCLLPSA-N 0.000 description 3
- PAQUJCSYVIBPLC-AVGNSLFASA-N Glu-Asp-Phe Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 PAQUJCSYVIBPLC-AVGNSLFASA-N 0.000 description 3
- YQPFCZVKMUVZIN-AUTRQRHGSA-N Glu-Val-Gln Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O YQPFCZVKMUVZIN-AUTRQRHGSA-N 0.000 description 3
- MIIVFRCYJABHTQ-ONGXEEELSA-N Gly-Leu-Val Chemical compound [H]NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O MIIVFRCYJABHTQ-ONGXEEELSA-N 0.000 description 3
- PDUHNKAFQXQNLH-ZETCQYMHSA-N Gly-Lys-Gly Chemical compound NCCCC[C@H](NC(=O)CN)C(=O)NCC(O)=O PDUHNKAFQXQNLH-ZETCQYMHSA-N 0.000 description 3
- NVTPVQLIZCOJFK-FOHZUACHSA-N Gly-Thr-Asp Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O NVTPVQLIZCOJFK-FOHZUACHSA-N 0.000 description 3
- ZZWUYQXMIFTIIY-WEDXCCLWSA-N Gly-Thr-Leu Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O ZZWUYQXMIFTIIY-WEDXCCLWSA-N 0.000 description 3
- NZGTYCMLUGYMCV-XUXIUFHCSA-N Ile-Lys-Arg Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N NZGTYCMLUGYMCV-XUXIUFHCSA-N 0.000 description 3
- PXKACEXYLPBMAD-JBDRJPRFSA-N Ile-Ser-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O)N PXKACEXYLPBMAD-JBDRJPRFSA-N 0.000 description 3
- PMGDADKJMCOXHX-UHFFFAOYSA-N L-Arginyl-L-glutamin-acetat Natural products NC(=N)NCCCC(N)C(=O)NC(CCC(N)=O)C(O)=O PMGDADKJMCOXHX-UHFFFAOYSA-N 0.000 description 3
- TYYLDKGBCJGJGW-UHFFFAOYSA-N L-tryptophan-L-tyrosine Natural products C=1NC2=CC=CC=C2C=1CC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 TYYLDKGBCJGJGW-UHFFFAOYSA-N 0.000 description 3
- 241000880493 Leptailurus serval Species 0.000 description 3
- USTCFDAQCLDPBD-XIRDDKMYSA-N Leu-Asn-Trp Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)N USTCFDAQCLDPBD-XIRDDKMYSA-N 0.000 description 3
- AXZGZMGRBDQTEY-SRVKXCTJSA-N Leu-Gln-Met Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(O)=O AXZGZMGRBDQTEY-SRVKXCTJSA-N 0.000 description 3
- CQGSYZCULZMEDE-UHFFFAOYSA-N Leu-Gln-Pro Natural products CC(C)CC(N)C(=O)NC(CCC(N)=O)C(=O)N1CCCC1C(O)=O CQGSYZCULZMEDE-UHFFFAOYSA-N 0.000 description 3
- FEHQLKKBVJHSEC-SZMVWBNQSA-N Leu-Glu-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC(C)C)C(O)=O)=CNC2=C1 FEHQLKKBVJHSEC-SZMVWBNQSA-N 0.000 description 3
- QNBVTHNJGCOVFA-AVGNSLFASA-N Leu-Leu-Glu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCC(O)=O QNBVTHNJGCOVFA-AVGNSLFASA-N 0.000 description 3
- KIZIOFNVSOSKJI-CIUDSAMLSA-N Leu-Ser-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N KIZIOFNVSOSKJI-CIUDSAMLSA-N 0.000 description 3
- IXHKPDJKKCUKHS-GARJFASQSA-N Lys-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCCCN)N IXHKPDJKKCUKHS-GARJFASQSA-N 0.000 description 3
- GQZMPWBZQALKJO-UWVGGRQHSA-N Lys-Gly-Arg Chemical compound [H]N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O GQZMPWBZQALKJO-UWVGGRQHSA-N 0.000 description 3
- AIRZWUMAHCDDHR-KKUMJFAQSA-N Lys-Leu-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O AIRZWUMAHCDDHR-KKUMJFAQSA-N 0.000 description 3
- PDIDTSZKKFEDMB-UWVGGRQHSA-N Lys-Pro-Gly Chemical compound [H]N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O PDIDTSZKKFEDMB-UWVGGRQHSA-N 0.000 description 3
- UGCIQUYEJIEHKX-GVXVVHGQSA-N Lys-Val-Glu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O UGCIQUYEJIEHKX-GVXVVHGQSA-N 0.000 description 3
- SPSSJSICDYYTQN-HJGDQZAQSA-N Met-Thr-Gln Chemical compound CSCC[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCC(N)=O SPSSJSICDYYTQN-HJGDQZAQSA-N 0.000 description 3
- FGWUALWGCZJQDJ-URLPEUOOSA-N Phe-Thr-Ile Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O FGWUALWGCZJQDJ-URLPEUOOSA-N 0.000 description 3
- KLYYKKGCPOGDPE-OEAJRASXSA-N Phe-Thr-Leu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O KLYYKKGCPOGDPE-OEAJRASXSA-N 0.000 description 3
- QEDMOZUJTGEIBF-FXQIFTODSA-N Ser-Arg-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(O)=O QEDMOZUJTGEIBF-FXQIFTODSA-N 0.000 description 3
- FMDHKPRACUXATF-ACZMJKKPSA-N Ser-Gln-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(O)=O FMDHKPRACUXATF-ACZMJKKPSA-N 0.000 description 3
- YMTLKLXDFCSCNX-BYPYZUCNSA-N Ser-Gly-Gly Chemical compound OC[C@H](N)C(=O)NCC(=O)NCC(O)=O YMTLKLXDFCSCNX-BYPYZUCNSA-N 0.000 description 3
- UIGMAMGZOJVTDN-WHFBIAKZSA-N Ser-Gly-Ser Chemical compound OC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O UIGMAMGZOJVTDN-WHFBIAKZSA-N 0.000 description 3
- QYSFWUIXDFJUDW-DCAQKATOSA-N Ser-Leu-Arg Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O QYSFWUIXDFJUDW-DCAQKATOSA-N 0.000 description 3
- GJFYFGOEWLDQGW-GUBZILKMSA-N Ser-Leu-Gln Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CO)N GJFYFGOEWLDQGW-GUBZILKMSA-N 0.000 description 3
- YUJLIIRMIAGMCQ-CIUDSAMLSA-N Ser-Leu-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YUJLIIRMIAGMCQ-CIUDSAMLSA-N 0.000 description 3
- AZWNCEBQZXELEZ-FXQIFTODSA-N Ser-Pro-Ser Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O AZWNCEBQZXELEZ-FXQIFTODSA-N 0.000 description 3
- OLKICIBQRVSQMA-SRVKXCTJSA-N Ser-Ser-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O OLKICIBQRVSQMA-SRVKXCTJSA-N 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- FQPDRTDDEZXCEC-SVSWQMSJSA-N Thr-Ile-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O FQPDRTDDEZXCEC-SVSWQMSJSA-N 0.000 description 3
- GXUWHVZYDAHFSV-FLBSBUHZSA-N Thr-Ile-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O GXUWHVZYDAHFSV-FLBSBUHZSA-N 0.000 description 3
- BIBYEFRASCNLAA-CDMKHQONSA-N Thr-Phe-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CC1=CC=CC=C1 BIBYEFRASCNLAA-CDMKHQONSA-N 0.000 description 3
- MNYNCKZAEIAONY-XGEHTFHBSA-N Thr-Val-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O MNYNCKZAEIAONY-XGEHTFHBSA-N 0.000 description 3
- SVGAWGVHFIYAEE-JSGCOSHPSA-N Trp-Gly-Gln Chemical compound C1=CC=C2C(C[C@H](N)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O)=CNC2=C1 SVGAWGVHFIYAEE-JSGCOSHPSA-N 0.000 description 3
- MBLJBGZWLHTJBH-SZMVWBNQSA-N Trp-Val-Arg Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)=CNC2=C1 MBLJBGZWLHTJBH-SZMVWBNQSA-N 0.000 description 3
- QOIKZODVIPOPDD-AVGNSLFASA-N Tyr-Cys-Gln Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(O)=O QOIKZODVIPOPDD-AVGNSLFASA-N 0.000 description 3
- QUILOGWWLXMSAT-IHRRRGAJSA-N Tyr-Gln-Gln Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O QUILOGWWLXMSAT-IHRRRGAJSA-N 0.000 description 3
- SSYBNWFXCFNRFN-GUBZILKMSA-N Val-Pro-Ser Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O SSYBNWFXCFNRFN-GUBZILKMSA-N 0.000 description 3
- OWFGFHQMSBTKLX-UFYCRDLUSA-N Val-Tyr-Tyr Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)O)N OWFGFHQMSBTKLX-UFYCRDLUSA-N 0.000 description 3
- 108010008685 alanyl-glutamyl-aspartic acid Proteins 0.000 description 3
- 108010069020 alanyl-prolyl-glycine Proteins 0.000 description 3
- 108010008355 arginyl-glutamine Proteins 0.000 description 3
- 108010069205 aspartyl-phenylalanine Proteins 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 108010078144 glutaminyl-glycine Proteins 0.000 description 3
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 description 3
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Natural products NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 3
- 108010010147 glycylglutamine Proteins 0.000 description 3
- 108010015792 glycyllysine Proteins 0.000 description 3
- 108010037850 glycylvaline Proteins 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 108010020755 prolyl-glycyl-glycine Proteins 0.000 description 3
- 239000012460 protein solution Substances 0.000 description 3
- 238000007789 sealing Methods 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 235000017281 sodium acetate Nutrition 0.000 description 3
- 239000001632 sodium acetate Substances 0.000 description 3
- 108010044292 tryptophyltyrosine Proteins 0.000 description 3
- WHVTZNGCKIEGPC-UHFFFAOYSA-N 4-(4-aminophenyl)-2,2,6,6-tetramethylcyclohex-3-en-1-amine;hydrochloride Chemical compound Cl.CC1(C)C(N)C(C)(C)CC(C=2C=CC(N)=CC=2)=C1 WHVTZNGCKIEGPC-UHFFFAOYSA-N 0.000 description 2
- NINQYGGNRIBFSC-CIUDSAMLSA-N Ala-Lys-Ser Chemical compound NCCCC[C@H](NC(=O)[C@@H](N)C)C(=O)N[C@@H](CO)C(O)=O NINQYGGNRIBFSC-CIUDSAMLSA-N 0.000 description 2
- JPOQZCHGOTWRTM-FQPOAREZSA-N Ala-Tyr-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O JPOQZCHGOTWRTM-FQPOAREZSA-N 0.000 description 2
- 101710132601 Capsid protein Proteins 0.000 description 2
- 101710094648 Coat protein Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 108091029865 Exogenous DNA Proteins 0.000 description 2
- NGBGZCUWFVVJKC-IRXDYDNUSA-N Gly-Tyr-Tyr Chemical compound C([C@H](NC(=O)CN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 NGBGZCUWFVVJKC-IRXDYDNUSA-N 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 2
- 101710125418 Major capsid protein Proteins 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 101710141454 Nucleoprotein Proteins 0.000 description 2
- 101001028244 Onchocerca volvulus Fatty-acid and retinol-binding protein 1 Proteins 0.000 description 2
- 101710083689 Probable capsid protein Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- OQPNSDWGAMFJNU-QWRGUYRKSA-N Ser-Gly-Tyr Chemical compound OC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 OQPNSDWGAMFJNU-QWRGUYRKSA-N 0.000 description 2
- PLQWGQUNUPMNOD-KKUMJFAQSA-N Ser-Tyr-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(O)=O PLQWGQUNUPMNOD-KKUMJFAQSA-N 0.000 description 2
- HUPLKEHTTQBXSC-YJRXYDGGSA-N Thr-Ser-Tyr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 HUPLKEHTTQBXSC-YJRXYDGGSA-N 0.000 description 2
- NOXKHHXSHQFSGJ-FQPOAREZSA-N Tyr-Ala-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 NOXKHHXSHQFSGJ-FQPOAREZSA-N 0.000 description 2
- VYQQQIRHIFALGE-UWJYBYFXSA-N Tyr-Ser-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 VYQQQIRHIFALGE-UWJYBYFXSA-N 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 230000034217 membrane fusion Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000012137 tryptone Substances 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- 101710131943 40S ribosomal protein S3a Proteins 0.000 description 1
- YSMPVONNIWLJML-FXQIFTODSA-N Ala-Asp-Pro Chemical compound C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(O)=O YSMPVONNIWLJML-FXQIFTODSA-N 0.000 description 1
- NCQMBSJGJMYKCK-ZLUOBGJFSA-N Ala-Ser-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O NCQMBSJGJMYKCK-ZLUOBGJFSA-N 0.000 description 1
- MUGAESARFRGOTQ-IGNZVWTISA-N Ala-Tyr-Tyr Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)O)N MUGAESARFRGOTQ-IGNZVWTISA-N 0.000 description 1
- XWGJDUSDTRPQRK-ZLUOBGJFSA-N Asn-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(N)=O XWGJDUSDTRPQRK-ZLUOBGJFSA-N 0.000 description 1
- CTQIOCMSIJATNX-WHFBIAKZSA-N Asn-Gly-Ala Chemical compound [H]N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(O)=O CTQIOCMSIJATNX-WHFBIAKZSA-N 0.000 description 1
- NJIKKGUVGUBICV-ZLUOBGJFSA-N Asp-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O NJIKKGUVGUBICV-ZLUOBGJFSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 241001524679 Escherichia virus M13 Species 0.000 description 1
- 101000978703 Escherichia virus Qbeta Maturation protein A2 Proteins 0.000 description 1
- 102000004961 Furin Human genes 0.000 description 1
- 108090001126 Furin Proteins 0.000 description 1
- YJIUYQKQBBQYHZ-ACZMJKKPSA-N Gln-Ala-Ala Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(O)=O YJIUYQKQBBQYHZ-ACZMJKKPSA-N 0.000 description 1
- SHERTACNJPYHAR-ACZMJKKPSA-N Gln-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(N)=O SHERTACNJPYHAR-ACZMJKKPSA-N 0.000 description 1
- KZKBJEUWNMQTLV-XDTLVQLUSA-N Gln-Ala-Tyr Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O KZKBJEUWNMQTLV-XDTLVQLUSA-N 0.000 description 1
- BRFJMRSRMOMIMU-WHFBIAKZSA-N Gly-Ala-Asn Chemical compound NCC(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(O)=O BRFJMRSRMOMIMU-WHFBIAKZSA-N 0.000 description 1
- 101710114810 Glycoprotein Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000929928 Homo sapiens Angiotensin-converting enzyme 2 Proteins 0.000 description 1
- HDOYNXLPTRQLAD-JBDRJPRFSA-N Ile-Ala-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)O)N HDOYNXLPTRQLAD-JBDRJPRFSA-N 0.000 description 1
- RPZFUIQVAPZLRH-GHCJXIJMSA-N Ile-Asp-Ala Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)O)N RPZFUIQVAPZLRH-GHCJXIJMSA-N 0.000 description 1
- SAEWJTCJQVZQNZ-IUKAMOBKSA-N Ile-Thr-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)N SAEWJTCJQVZQNZ-IUKAMOBKSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 101710085938 Matrix protein Proteins 0.000 description 1
- 101710127721 Membrane protein Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- SFECXGVELZFBFJ-VEVYYDQMSA-N Pro-Asp-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SFECXGVELZFBFJ-VEVYYDQMSA-N 0.000 description 1
- KWMZPPWYBVZIER-XGEHTFHBSA-N Pro-Ser-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O KWMZPPWYBVZIER-XGEHTFHBSA-N 0.000 description 1
- GZNYIXWOIUFLGO-ZJDVBMNYSA-N Pro-Thr-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O GZNYIXWOIUFLGO-ZJDVBMNYSA-N 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- LVVBAKCGXXUHFO-ZLUOBGJFSA-N Ser-Ala-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(O)=O LVVBAKCGXXUHFO-ZLUOBGJFSA-N 0.000 description 1
- BRKHVZNDAOMAHX-BIIVOSGPSA-N Ser-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CO)N BRKHVZNDAOMAHX-BIIVOSGPSA-N 0.000 description 1
- YQHZVYJAGWMHES-ZLUOBGJFSA-N Ser-Ala-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O YQHZVYJAGWMHES-ZLUOBGJFSA-N 0.000 description 1
- IOVHBRCQOGWAQH-ZKWXMUAHSA-N Ser-Gly-Ile Chemical compound [H]N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(O)=O IOVHBRCQOGWAQH-ZKWXMUAHSA-N 0.000 description 1
- GZFAWAQTEYDKII-YUMQZZPRSA-N Ser-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CO GZFAWAQTEYDKII-YUMQZZPRSA-N 0.000 description 1
- JCLAFVNDBJMLBC-JBDRJPRFSA-N Ser-Ser-Ile Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O JCLAFVNDBJMLBC-JBDRJPRFSA-N 0.000 description 1
- UBTNVMGPMYDYIU-HJPIBITLSA-N Ser-Tyr-Ile Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O UBTNVMGPMYDYIU-HJPIBITLSA-N 0.000 description 1
- 101710167605 Spike glycoprotein Proteins 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- VIBXMCZWVUOZLA-OLHMAJIHSA-N Thr-Asn-Asn Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(=O)N)C(=O)O)N)O VIBXMCZWVUOZLA-OLHMAJIHSA-N 0.000 description 1
- DCLBXIWHLVEPMQ-JRQIVUDYSA-N Thr-Asp-Tyr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 DCLBXIWHLVEPMQ-JRQIVUDYSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- VCXWRWYFJLXITF-AUTRQRHGSA-N Tyr-Ala-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 VCXWRWYFJLXITF-AUTRQRHGSA-N 0.000 description 1
- DKKHULUSOSWGHS-UWJYBYFXSA-N Tyr-Asn-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC1=CC=C(C=C1)O)N DKKHULUSOSWGHS-UWJYBYFXSA-N 0.000 description 1
- KHPLUFDSWGDRHD-SLFFLAALSA-N Tyr-Tyr-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC3=CC=C(C=C3)O)N)C(=O)O KHPLUFDSWGDRHD-SLFFLAALSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 108010087924 alanylproline Proteins 0.000 description 1
- 108010070783 alanyltyrosine Proteins 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 229940125644 antibody drug Drugs 0.000 description 1
- 108010093581 aspartyl-proline Proteins 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000005757 colony formation Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 102000048657 human ACE2 Human genes 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000010414 supernatant solution Substances 0.000 description 1
- 108010033670 threonyl-aspartyl-tyrosine Proteins 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 108010020532 tyrosyl-proline Proteins 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/10—Detection of antigens from microorganism in sample from host
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Communicable Diseases (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Tropical Medicine & Parasitology (AREA)
Abstract
A monoclonal antibody and its application against new coronavirus spike protein non-RBD area, this monoclonal antibody binds with specificity of new coronavirus spike protein RBD area, include the complementarity determining region CDRH1 of the heavy chain variable region, CDRH2, CDRH3 and complementarity determining region CDRL1, CDRL2, CDRL3 of the light chain variable region; the monoclonal antibody aiming at the non-RBD region of the spinous process protein of the new coronavirus has high titer and strong specificity, can be efficiently expressed, can be specifically combined with the region outside the RBD region of the spinous process protein on the surface of the SARS-CoV-2 of the new coronavirus, is used for qualitative or quantitative detection of the new coronavirus, can neutralize certain toxicity of the new coronavirus, weakens the toxicity of the virus, and plays a role in preventing or/and treating pneumonia of the new coronavirus.
Description
Technical Field
The invention relates to the technical field of biological engineering, in particular to the technical field of cellular immunology and molecular biology, and more particularly to a monoclonal antibody aiming at a non-RBD region of a new coronavirus spike protein and application thereof.
Background
The Membrane protein of the new coronavirus mainly comprises surface spinous process protein (Spike protein, S protein) and Membrane protein (M protein), wherein the S protein is glycoprotein and mainly acts on cell adhesion and cell Membrane fusion, and is decomposed into S1 and S2 by furin or other enzymes in a plurality of mammals, wherein the S1 is provided with a receptor attachment site, and the S2 mainly shows fusion activity. The novel coronaviruses can bind to a variety of cellular receptors, of which angiotensin converting enzyme 2(ACE2) is one of the receptors of cell surface coronaviruses as a peptidase. There is a region within S1 that binds tightly to ACE2, which we refer to as the Receptor Binding Domain (RBD), and is a key element in the interaction between virus and receptor. Research shows that the RBD only needs to change a few amino acids, cross-species infection can occur, and the RBD comprises an important virus neutralizing epitope and is very critical to improving immune response.
The spinous process protein plays a role in the combination of virus and host cell membrane receptor and membrane fusion, and is an important action site of host neutralizing antibody and a key target of vaccine design. The spinous process protein of SARS-CoV-2(2019-nCoV) interacts with human ACE2 to infect respiratory epithelial cells in humans.
Antibodies are important glycoprotein molecules in the mammalian immune system. The antibody molecule consists of two Heavy chains (Heavy chain) and two Light chains (Light chain), wherein the Heavy chains are divided into Variable regions (VH) and three Constant regions (Constant regions of Heavy chain; CH1, CH2, CH3), and the Light chains consist of one Variable region (VL) and one Constant region (CL). The variable region has a function of binding to an antigen, and varies depending on the individual antibody, while the constant region of the antibody varies depending on the species and subtype of the antibody. The antibody heavy chain variable region comprises three Complementarity determining regions (CDRH 1, CDRH2, CDRH3) and the light chain variable region also comprises three Complementarity determining regions (CDRL 1, CDRL2, and CDRL 3), which are also known as hypervariable regions, and which directly bind to an epitope of an antigen.
At present, no effective medicine is available in the treatment of the new coronary pneumonia, the treatment effect is not obvious by adopting the conventional antibiotic medicine, and some medicines have serious toxic and side effects. On the other hand, since antibody drugs play an important role in the treatment of infectious diseases and autoimmune diseases and are more targeted, the development of monoclonal antibodies against novel coronaviruses is of great importance.
Disclosure of Invention
In order to solve the problems, the invention aims to provide a monoclonal antibody aiming at a non-RBD region of a novel coronavirus spike protein and application thereof.
In order to achieve the purpose, the invention is realized by the following technical scheme:
the invention discloses a monoclonal antibody aiming at a non-RBD region of spike protein of SARS-CoV-2 of a new coronavirus, which is specifically combined with the non-RBD region of spike glycoprotein of SARS-CoV-2 of the new coronavirus, and comprises complementarity determining regions CDRH1, CDRH2, CDRH3 of a heavy chain variable region and complementarity determining regions CDRL1, CDRL2 and CDRL3 of a light chain variable region; the amino acid sequences of the complementarity determining regions CDRH1, CDRH2 and CDRH3 of the heavy chain variable region are SEQ ID NO: 2. SEQ ID NO: 3 and SEQ ID NO: 4; the amino acid sequences of the complementarity determining regions CDRL1, CDRL2 and CDRL3 of the light chain variable region are SEQ ID NO: 6. SEQ ID NO: 7 and SEQ ID NO: 8.
preferably, a monoclonal antibody against the non-RBD region of the spike protein of the SARS-CoV-2 of the novel coronavirus is named A4, and the amino acid sequence of the heavy chain variable region of the monoclonal antibody is SEQ ID NO: 1, the amino acid sequence of the light chain variable region of the monoclonal antibody is SEQ ID NO: 5.
the invention also includes an isolated nucleic acid molecule encoding a monoclonal antibody as described in any one of the above.
The invention also includes an expression vector comprising a nucleic acid molecule as described above, which expression vector comprises, in addition to the nucleic acid molecule as described above, an expression control sequence operably linked to the sequence of said nucleic acid molecule.
An expression vector refers to a nucleic acid vehicle into which a polynucleotide encoding the a4 antibody can be inserted and the a4 antibody expressed. The vector may be transformed, transduced or transfected into a host cell so that the genetic material elements it carries are expressed within the host cell. Types of vectors include bacterial plasmids, bacteriophages, yeast plasmids, plant cell viruses, mammalian cell viruses such as adenoviruses, retroviruses, or other vectors well known in the art. In principle, any vector may be used as long as it is replicable and stable in the host. In addition to the origin of replication, expression vectors may also contain marker genes and other translational control elements.
The invention also includes a host cell comprising a nucleic acid molecule as described above or an expression vector as described above.
The host cell expressing the a4 antibody can be a prokaryotic cell, such as a bacterial cell; or lower eukaryotic cells, such as yeast cells; or higher eukaryotic cells, such as mammalian cells. Representative examples are: escherichia coli, streptomyces; bacterial cells of salmonella typhimurium: fungal cells such as yeast; a plant cell; insect cells of Drosophila S2 or Sf 9; CHO, COS, 293 cells or Bowes melanoma cells.
The invention also includes a method for detecting the level of the novel coronavirus SARS-CoV-2 for non-diagnostic purposes, comprising the steps of:
extracting a sample containing new coronavirus SARS-CoV-2;
contacting the sample obtained in the step I with the monoclonal antibody A4;
and thirdly, detecting the immunoreaction of the sample and the monoclonal antibody.
The invention also includes the application of the monoclonal antibody aiming at the non-RBD region of the spinous process protein of the new coronavirus SARS-CoV-2 in the preparation of a detection product of the new coronavirus SARS-CoV-2.
The detection product includes, but is not limited to, a detection reagent, a kit, a chip or a test paper. Any assay product capable of detecting SARS-CoV-2 comprising a binding molecule as described above is included within the scope of the invention.
The invention also includes the application of the monoclonal antibody aiming at the non-RBD region of the spike protein of the new coronavirus SARS-CoV-2 in the preparation of the medicine for inhibiting the new coronavirus SARS-CoV-2.
The invention also includes the application of the monoclonal antibody aiming at the non-RBD region of the spike protein of the new coronavirus SARS-CoV-2 in the preparation of a pharmaceutical preparation for preventing or treating pneumonia caused by the new coronavirus SARS-CoV-2.
The terms "new coronavirus SARS-CoV-2" and "SARS-CoV-2 virus", "new coronavirus", "SARS-CoV-2" and "new coronavirus SARS-CoV-2" used in the present invention can be used interchangeably.
Compared with the prior art, the invention has the following advantages:
the monoclonal antibody aiming at the non-RBD region of the spinous process protein of the new coronavirus has high titer and strong specificity, can be efficiently expressed, can be specifically combined with the region outside the RBD region of the spinous process protein on the surface of the SARS-CoV-2 of the new coronavirus, is used for qualitative or quantitative detection of the new coronavirus, can neutralize certain toxicity of the new coronavirus, weakens the toxicity of the virus, and achieves the purpose of preventing or/and treating the new coronavirus.
The phage display technology inserts exogenous DNA into the gene of phage coding coat protein, so that the expression product corresponding to the exogenous DNA fragment is fused in the coat protein of the phage to form fusion protein, and the fusion protein is displayed on the surface of the phage. Has the following remarkable advantages: direct physical connection between the genotype and the phenotype is established, so that the screening is simple, convenient and efficient. The invention screens the antibodies which can be combined with the S protein of the new coronavirus SARS-CoV-2 from the Tomlinson I + J phage display synthetic antibody library, and the antibodies have important application values in the aspects of detecting the new coronavirus and reducing the virus toxicity.
Drawings
FIG. 1 shows the results of enzyme-linked immunoassay for the antigen binding performance of phages obtained by panning an antibody library;
FIG. 2 shows the results of ELISA assay for the antigen specificity of monoclonal antibody A4;
FIG. 3 shows the results of ELISA assay for the antigen specificity of monoclonal antibody A2;
FIG. 4 shows the results of ELISA assay for the antigen specificity of monoclonal antibody C3;
FIG. 5 is a schematic diagram of the principle of detecting new coronavirus using elutriated antibody;
FIG. 6 shows the results of ELISA using Fab fragment of A4 antibody in combination with A2 to detect virus S protein;
FIG. 7 shows the results of ELISA using Fab fragment of A4 antibody in combination with C3 to detect virus S protein.
Detailed Description
The present invention is directed to monoclonal antibodies against the non-RBD region of the spinous process protein of the novel coronavirus and uses thereof, as further illustrated by the following examples, which are intended to illustrate and not to limit the present invention, and the invention is susceptible to modification in accordance with the spirit of the present invention and within the scope of the appended claims.
The invention is further described with reference to specific examples.
Example 1
Amplification of a phage display antibody library:
mu.L of E.coli TG-1 (MRC HGMP resources center, UK) containing Tomlinson I + J phage display antibody library was inoculated into 25mL of 2YT medium (1.6% Tryptone, 1% Yeast Extract, 0.5% NaCl) containing 100. mu.g/mL ampicillin and 1% glucose, and cultured at 37 ℃ to OD600At 0.4, add 109cfu (Colony Formation Unit) KM13 helper phage (British MRC HGMP resource center), 1 hour after infection at 37 ℃, 3000g centrifugation for 30 minutes, discarding the supernatant, using 50mL (1.6% Tryptone, 1% Yeast Extract, 0.5% NaCl) of 2YT medium containing 100. mu.g/mL ampicillin, 50. mu.g/mL kanamycin and 0.1% glucose to suspend the cells, shaking the cells at 30 ℃ at 250rpm for 16 hours, centrifuging the culture solution at 5000g for 30 minutes the next day, separating and recovering 40mL of the supernatant, adding 10mL of PEG/NaCl solution to the supernatant, mixing well, standing on ice for 30 minutes, centrifuging at 5000g for 30 minutes, discarding the supernatant, adding 2mL of sterile solution to dissolve the precipitate, as phage display antibody library solution, titrating the phage display antibody library with E.coli, and preparing an antibody library having a concentration of 1012cfu/mL。
Second, panning of phage display antibody library
Adding 100 μ L of PBS solution containing 10 μ g/mLSARS-CoV-2 virus S protein (Nanjing Kingsler Biotech Co., Ltd.) into 10 wells of a 96-well microplate, incubating overnight at 4 deg.C, discarding the antigen solution the next time, adding 200 μ L of PBS solution containing 2% skimmed milk powder into each well, incubating for 2 hours at 25 deg.C for blocking, washing for 3 times with PBST, and adding 100 μ L of phage solution (R0; each well contains 10 μ L)9cfu phage) were incubated at room temperature for 2 hours, and after washing with PBST, phage bound to viral S protein were eluted by adding 100 μ L trypsin per well.
Culturing TG-1 E.coli to OD600To 0.4, 500. mu.L of the dissolved phage solution was added to 4mL of the bacterial solution, infected at 37 ℃ for 30 minutes, centrifuged at 5000g for 20 minutes, the supernatant was discarded, the cells were suspended in 2YT medium containing 100. mu.g/mL ampicillin, 50. mu.g/mL kanamycin and 0.1% glucose, and shaken at 30 ℃ and 250rpm for 16 hours; centrifuging culture solution for 30 minutes at 5000g the next day, separating and recovering supernatant, adding 1/5 volume PEG/NaCl solution into the supernatant solution, mixing well, standing on ice for 30 minutes, centrifuging for 30 minutes at 5000g, discarding supernatant, adding 200 μ L sterile PBS solution as phage solution after first enrichment (R1); repeating the steps to respectively obtain phage solutions R2 and R3; an enzyme-linked immunosorbent assay is performed,and verifying the binding specificity and binding performance of the phage display antibody library obtained in the panning process and the S protein.
The enzyme-linked immunosorbent assay was performed as follows: 100. mu.L of PBS containing neocoronavirus S protein (2. mu.g/mL) or bovine serum albumin BSA (2. mu.g/mL) was added to a 96-well plate, overnight at 4 ℃, the antigen solution was discarded the next day, 200. mu.L of PBS containing 2% skim milk powder was added, and the plate was incubated at 25 ℃ for 2 hours and then blocked. The microplate was washed 3 times with PBS containing 0.1% Tween 20, and diluted R0, R2 and R3 phage solutions (10) were added9cfu/well), incubation at 25 ℃ for 1 hour, washing the microplate with PBST solution, addition of HRP-labeled mouse anti-M13 antibody, incubation for 1 hour, washing the plate with PBST, addition of HRP substrate TMBZ (prepared with sodium acetate solution pH6.0, containing 1/10000 diluted 30% H2O2) After color development, absorbance at 450nm is detected by a microplate reader, a histogram is drawn, and the binding performance of the phage antibody, the S protein and the BSA are obtained by comparing each round.
The results of the enzyme-linked immunosorbent assay are shown in fig. 1, and when the binding capacities of the phage libraries R0, R2 and R3 obtained in the phage panning process and the S protein are compared, it is found that the binding capacity of the phage solution R2 obtained in the second panning process and the S protein is significantly increased, and the binding performance to BSA is very weak and unchanged, which indicates that the antibodies against the new coronavirus S protein in the constructed phage display antibody library are enriched.
Thirdly, screening of monoclonal antibody
Culturing TG-1 E.coli to OD600Taking 100 mu L of elutriation sieve R2 phage antibody library dissolved out phage solution for infecting 200 mu L of escherichia coli bacterial solution, incubating for 30 minutes at 37 ℃, coating the bacterial solution on a 2YT culture medium plate containing 100 mu g/mL ampicillin, 50 mu g/mL kanamycin and 1% glucose, and culturing overnight at 37 ℃; the next day, 96 colonies were picked and inoculated onto 96-well plates, and cultured at 37 ℃ to OD600To 0.4, M13 phage was added to each well, after infection, the supernatant was removed by centrifugation at 5000g for 20 minutes, 200. mu.L of 2YT medium containing 100. mu.g/mL ampicillin, 50. mu.g/mL kanamycin and 0.1% glucose was added to each well, the cells were suspended,culturing at 30 deg.C at 250rpm for 16 hr; the culture solution is centrifuged for 30 minutes at 5000g the next day, the supernatant is separated and recovered, enzyme-linked immunosorbent assay is performed, and the binding specificity and the binding performance of each monoclonal antibody and S protein are verified.
The enzyme-linked immunosorbent assay was performed as follows: mu.L of PBS solution containing virus S protein (1 mu g/mL) is added into a 96-well enzyme label plate, the mixture is kept overnight at 4 ℃, the antigen solution is discarded the next day, 200 mu.L of PBS solution containing 2% skimmed milk powder is added, the mixture is incubated for 2 hours at 25 ℃, and the enzyme label plate is blocked. Washing the ELISA plate with PBS solution containing 0.1% Tween 20 for 3 times, adding phage solution, incubating at 25 deg.C for 1 hr, washing the ELISA plate with PBST solution, adding HRP-labeled mouse anti-M13 antibody, incubating for 1 hr, washing the plate with PBST, adding HRP substrate TMBZ (prepared with sodium acetate solution of pH6.0, containing 1/10000 diluted 30% H)2O2) After the development, absorbance at 450nm and absorbance at 630nm are detected by a microplate reader, a bar graph is drawn, and the binding performance of the phage antibody of each clone with S protein and bovine serum albumin is compared.
According to the experimental result, 6 micropores coated with S protein are dark in color, the absorbance is 1.40, 1.30, 1.35, 1.05, 1.10 and 0.80 respectively, bacteria corresponding to the micropores are cultured, plasmids are extracted from the antibody in the micropore with the absorbance of 1.35, gene sequencing is carried out, and the antibody is named as monoclonal antibody A4 according to the position of the antibody in the micropore plate (A row and 4 columns); extracting plasmids from the antibody in the micropore with the absorbance of 1.4 and carrying out gene sequencing, wherein the antibody is named as a monoclonal antibody A2 according to the position (A row and 2 columns) of the antibody in the micropore plate; extracting plasmids from the antibody in the micropore with the absorbance of 1.1 and carrying out gene sequencing, wherein the antibody is named as a monoclonal antibody C3 according to the position (row C and column 3) of the antibody in the micropore plate; by comparing with the antibody sequences registered in the antibody gene library, no sequence identical to the antibody gene of the present invention is found, indicating that these antibodies are novel antibodies. The details of the amino acid sequence of the antibody are as follows.
The heavy chain variable region sequence of the A4 antibody is SEQ ID NO: 1, CDRH1 sequence of SEQ ID NO: 2; the CDRH2 sequence is SEQ ID NO: 3; the CDRH3 sequence is SEQ ID NO: 4;
the variable region sequence of the light chain of the A4 antibody is SEQ ID NO: 5, CDRL1 sequence is SEQ ID NO: 6; the CDRL2 sequence is SEQ ID NO: 7; the CDRL3 sequence is SEQ ID NO: 8.
the heavy chain variable region sequence of the A2 antibody is SEQ ID NO: 9, CDRH1 sequence as SEQ ID NO: 10; the CDRH2 sequence is SEQ ID NO: 11; the CDRH3 sequence is SEQ ID NO: 12;
the variable region sequence of the light chain of the A2 antibody is SEQ ID NO: 13, CDRL1 sequence of SEQ ID NO: 14; the CDRL2 sequence is SEQ ID NO: 15; the CDRL3 sequence is SEQ ID NO: 16.
the heavy chain variable region sequence of the C3 antibody is SEQ ID NO: 17, CDRH1 sequence of SEQ ID NO: 18; the CDRH2 sequence is SEQ ID NO: 19; the CDRH3 sequence is SEQ ID NO: 20;
the variable region sequence of the light chain of the C3 antibody is SEQ ID NO: 21, CDRL1 sequence of SEQ ID NO: 22; the CDRL2 sequence is SEQ ID NO: 23; the CDRL3 sequence is SEQ ID NO: 24.
the sequence specific information related to the A4 of the invention is as follows:
SEQ ID NO:1:
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSYITNNGANTSYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKSYATFDYWGQGTLVTVSS;
SEQ ID NO:2:GFTFSSYA;
SEQ ID NO:3:ITNNGANT;
SEQ ID NO:4:AKSYATFDY;
SEQ ID NO:5:
DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYNASGLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQAAYYPTTFGQGTKVEIKR;
SEQ ID NO:6:QSISSY;
SEQ ID NO:7:NAS;
SEQ ID NO:8:QQAAYYPTT;
the sequence specific information related to the A2 of the invention is as follows:
SEQ ID NO:9:
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSGIDASGYYTSYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDAYTFDYWGQGTLVTVSS;
SEQ ID NO:10:
GFTFSSYA;
SEQ ID NO:11:
IDASGYYT;
SEQ ID NO:12:
AKDAYTFDY;
SEQ ID NO:13:
DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYSASYLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQASADPDTFGQGTKVEIKR;
SEQ ID NO:14:
QSISSY;
SEQ ID NO:15:
SAS;
SEQ ID NO:16:
QQASADPDT。
the sequence specific information related to the invention C3 is as follows:
SEQ ID NO:17:
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSSIASSGYYTDYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDADSFDYWGQGTLVTVSS;
SEQ ID NO:18:GFTFSSYA;
SEQ ID NO:19:IASSGYYT;
SEQ ID NO:20:AKDADSFDY;
SEQ ID NO:21:
DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASYLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQAYSAPSTFGQGTKVEIKR;
SEQ ID NO:22:QSISSY;
SEQ ID NO:23:AAS;
SEQ ID NO:24:QQAYSAPST。
fourth, antigen specificity of monoclonal antibody
Adding 100 mu L of new coronavirus S protein, S-RBD protein and BSA protein solution with the concentration of 1 mu g/mL into a 96-hole enzyme label plate, staying overnight at 4 ℃, discarding the protein solution the next time, adding 200 mu L of 2% skimmed milk powder-PBS solution, incubating for 2 hours at 25 ℃, and sealing the enzyme label plate; after washing the microplate 3 times with PBS containing 0.1% Tween 20, 100. mu.L of the reagent was added to each well for dilutionThe phage display antibody solution of (1) was incubated at 25 ℃ for 1 hour, the microplate was washed with PBST solution, HRP-labeled mouse anti-M13 antibody was added, and after incubation for 1 hour, the plate was washed with PBST, and HRP substrate TMBZ (prepared with sodium acetate solution pH6.0, containing 1/10000 diluted 30% H) was added2O2) After the development, absorbance of 450nm is detected by an enzyme-labeling instrument, a histogram is drawn, and the binding performance of the phage antibody of each clone and the coating protein is compared.
The results of the ELISA test using monoclonal antibody A4 are shown in FIG. 2, in which A4 binds to S protein but has weak binding ability to S-RBD protein, indicating that A4 binds mainly to the region other than the RBD region of S protein, and monoclonal antibody A4 does not bind to coated BSA, indicating that the binding of antibody to S protein is specific.
The results of ELISA with monoclonal antibody A2 are shown in FIG. 3, where A2 binds both S protein and S-RBD protein, and A2 does not bind coated BSA as an antibody recognizing the RBD region of S protein, indicating that the binding of monoclonal antibody A2 to S protein is specific.
The results of ELISA with monoclonal antibody C3 are shown in FIG. 4, in which C3 binds to both S protein and S-RBD protein, and C3 does not bind to coated BSA as an antibody recognizing the RBD region of S protein, indicating that the binding of monoclonal antibody C3 to S protein is specific.
Fifthly, detecting the novel coronavirus S protein by using the Fab fragment of the A2 antibody and the A4 antibody displayed by phage
The detection principle is shown in FIG. 5, the A2 protein and phage-displayed A4 are used for detecting the S protein of the new coronavirus, a Fab fragment of an A2 antibody is coated in the pores of a 96-pore microplate (the heavy chain variable region gene and the light chain variable region gene of the A2 antibody are cloned to a pDeng 1 phage display carrier, the Escherichia coli HB2151 is transformed, the transformed Escherichia coli is cultured, then the culture supernatant is taken, a histidine tag is used for purification to obtain the Fab fragment of the A2 antibody), after the microplate is closed, the S protein or BSA protein is added, the phage-displayed A4 antibody is added after the plate is washed, then the anti-phage antibody marked with horse radish peroxidase is added, the substrate is added after the plate is washed for color development, when the sample does not contain the S protein of the new coronavirus or contains the BSA protein, the reaction system does not develop color, and the more virus S protein is in the sample, the A4 of the phage display plate is more, the more anti-phage antibody captured correspondingly, the darker the color of the enzyme-added substrate after development, and the method can be used to determine whether the sample contains virus S1 protein, and can also be used to detect whether SARS-CoV-2 virus exists in the sample.
The specific operation is as follows: adding A2 antibody Fab fragment into the hole of 96-hole enzyme label plate, staying overnight at 4 ℃, discarding the liquid in the hole, adding 200 μ L of 2% skimmed milk powder-PBS solution, standing at room temperature for two hours, and sealing the enzyme label plate. After washing the plate, 100. mu.L of a solution containing the S protein of the neocoronavirus or Bovine Serum Albumin (BSA) was added to the wells, incubated at 25 ℃ for 1 hour, the well-containing solution was removed, the plate was washed with a PBS solution (PBST solution) containing 0.1% Tween 20, and a solution of A4 antibody (10) displayed by phage was added9cfu/mL), incubating at 25 ℃ for 1 hour, washing the plate, adding an anti-phage antibody solution (1 mu g/mL) marked with horseradish peroxidase (HRP), incubating at 25 ℃ for 1 hour, removing the solution in the hole, washing the plate for 3 times by PBST, finally adding an HRP substrate 3, 3, 5, 5-tetramethylbenzidine hydrochloride (TMBZ) solution for color development, measuring the absorbance of the solution in the hole at 450nm and 630nm, making a histogram, and comparing the binding capacity of the antibody with the S protein of the new coronavirus and the bovine serum albumin.
As shown in FIG. 6, the results of detecting the virus S protein by the combination of the A2 antibody and phage-displayed A4 antibody, respectively, show the name of the detection protein on the horizontal axis and the absorbance of the solution in the wells corresponding to the wells on the vertical axis. The absorbance of the wells of the enzyme-labeled plate containing the virus S protein in the solution of the combination of A2 and A4 was 0.55, and the absorbance of the wells added with BSA was 0.03, indicating that the combination of A2 and A4 can be used to detect the new coronavirus S protein and new coronavirus in the solution.
Sixthly, detecting the novel coronavirus S protein by using a C3 antibody Fab fragment and a phage-displayed A4 antibody
The detection principle is shown in figure 5, C3 protein and phage-displayed A4 are used for detecting S protein of the new coronavirus, Fab fragment of C3 antibody is coated in the pores of a 96-pore microporous plate (heavy chain variable region gene and light chain variable region gene of C3 antibody are cloned to pDeng 1 phage display carrier, transformed Escherichia coli HB2151 is transformed, the transformed Escherichia coli is cultured, culture supernatant is taken, histidine tag is used for purification to obtain Fab fragment of C3 antibody), after the microporous plate is closed, S protein or BSA protein solution is added, phage-displayed A4 antibody is added after washing the plate, then anti-phage antibody marked with horse radish peroxidase is added, substrate is added after washing the plate for color development, when the sample has no new coronavirus S protein or BSA protein, the reaction system does not develop color, when the virus S protein exists, and the system develops color, and the more virus S protein exists in the sample, the more A4 phage that are captured to the microplate by the virus S protein, the more anti-phage antibodies that are captured accordingly, and the darker the color of the enzyme-added substrate after development, it is possible to determine whether the sample contains virus S1 protein by this method, which can also be used to detect the presence of SARS-CoV-2 virus in the sample.
The specific operation is as follows: adding the Fab fragment of the C3 antibody into the hole of the 96-hole enzyme label plate, staying overnight at 4 ℃, discarding the liquid in the hole the next time, adding 200 mu L of 2% skimmed milk powder-PBS solution, standing for two hours at room temperature, and sealing the enzyme label plate. After washing the plate, 100. mu.L of a solution containing the S protein of the neocoronavirus or Bovine Serum Albumin (BSA) was added to the wells, incubated at 25 ℃ for 1 hour, the well-containing solution was removed, the plate was washed with a PBS solution (PBST solution) containing 0.1% Tween 20, and a solution of A3 antibody (10) displayed by phage was added9cfu/mL), incubating at 25 ℃ for 1 hour, washing the plate, adding an anti-phage antibody solution (1 mu g/mL) marked with horseradish peroxidase (HRP), incubating at 25 ℃ for 1 hour, removing the solution in the hole, washing the plate for 3 times by PBST, finally adding an HRP substrate 3, 3, 5, 5-tetramethylbenzidine hydrochloride (TMBZ) solution for color development, measuring the absorbance of the solution in the hole at 450nm and 630nm, making a histogram, and comparing the binding capacity of the antibody with the S protein of the new coronavirus and the bovine serum albumin.
As shown in FIG. 7, the C3 antibody was combined with phage-displayed A4 to detect the virus S protein, and the horizontal axis represents the name of the detection protein and the vertical axis represents the absorbance of the solution in the wells corresponding to the enzyme. The absorbance of the wells of the elisa plate containing the virus S protein in the solution of the combination of C3 and a4 was 0.52, while the absorbance of the wells to which BSA was added was 0.02, indicating that the combination with a4 can be used to detect new coronavirus S protein and new coronavirus in the solution.
Sequence listing
<110> Weifang medical college
<120> monoclonal antibody aiming at non-RBD region of new coronavirus spike protein and application thereof
<130> 20200904A-4
<141> 2020-09-04
<150> 2020104148681
<151> 2020-05-15
<160> 24
<170> SIPOSequenceListing 1.0
<210> 1
<211> 116
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 1
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Tyr Ile Thr Asn Asn Gly Ala Asn Thr Ser Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Ser Tyr Ala Thr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val
100 105 110
Thr Val Ser Ser
115
<210> 2
<211> 8
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 2
Gly Phe Thr Phe Ser Ser Tyr Ala
1 5
<210> 3
<211> 8
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 3
Ile Thr Asn Asn Gly Ala Asn Thr
1 5
<210> 4
<211> 9
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 4
Ala Lys Ser Tyr Ala Thr Phe Asp Tyr
1 5
<210> 5
<211> 108
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 5
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Asn Ala Ser Gly Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ala Ala Tyr Tyr Pro Thr
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
100 105
<210> 6
<211> 6
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 6
Gln Ser Ile Ser Ser Tyr
1 5
<210> 7
<211> 3
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 7
Asn Ala Ser
1
<210> 8
<211> 9
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 8
Gln Gln Ala Ala Tyr Tyr Pro Thr Thr
1 5
<210> 9
<211> 116
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 9
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Gly Ile Asp Ala Ser Gly Tyr Tyr Thr Ser Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Asp Ala Tyr Thr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val
100 105 110
Thr Val Ser Ser
115
<210> 10
<211> 8
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 10
Gly Phe Thr Phe Ser Ser Tyr Ala
1 5
<210> 11
<211> 8
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 11
Ile Asp Ala Ser Gly Tyr Tyr Thr
1 5
<210> 12
<211> 9
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 12
Ala Lys Asp Ala Tyr Thr Phe Asp Tyr
1 5
<210> 13
<211> 108
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 13
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Ser Ala Ser Tyr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ala Ser Ala Asp Pro Asp
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
100 105
<210> 14
<211> 6
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 14
Gln Ser Ile Ser Ser Tyr
1 5
<210> 15
<211> 3
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 15
Ser Ala Ser
1
<210> 16
<211> 9
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 16
Gln Gln Ala Ser Ala Asp Pro Asp Thr
1 5
<210> 17
<211> 116
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 17
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ser Ile Ala Ser Ser Gly Tyr Tyr Thr Asp Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Asp Ala Asp Ser Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val
100 105 110
Thr Val Ser Ser
115
<210> 18
<211> 8
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 18
Gly Phe Thr Phe Ser Ser Tyr Ala
1 5
<210> 19
<211> 8
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 19
Ile Ala Ser Ser Gly Tyr Tyr Thr
1 5
<210> 20
<211> 9
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 20
Ala Lys Asp Ala Asp Ser Phe Asp Tyr
1 5
<210> 21
<211> 108
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 21
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Ala Ala Ser Tyr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ala Tyr Ser Ala Pro Ser
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
100 105
<210> 22
<211> 6
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 22
Gln Ser Ile Ser Ser Tyr
1 5
<210> 23
<211> 3
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 23
Ala Ala Ser
1
<210> 24
<211> 9
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 24
Gln Gln Ala Tyr Ser Ala Pro Ser Thr
1 5
Claims (9)
1. A monoclonal antibody directed against non-RBD regions of the spinous process protein of a novel coronavirus which is characterized in that: the monoclonal antibody is specifically combined with a non-RBD region of a new coronavirus spike glycoprotein and comprises complementarity determining regions CDRH1, CDRH2 and CDRH3 of a heavy chain variable region and complementarity determining regions CDRL1, CDRL2 and CDRL3 of a light chain variable region; the amino acid sequences of the complementarity determining regions CDRH1, CDRH2 and CDRH3 of the heavy chain variable region are SEQ ID NO: 2. SEQ ID NO: 3 and SEQ ID NO: 4; the amino acid sequences of the complementarity determining regions CDRL1, CDRL2 and CDRL3 of the light chain variable region are SEQ ID NO: 6. SEQ ID NO: 7 and SEQ ID NO: 8.
2. the monoclonal antibody against non-RBD region of the spinous protein of a neocoronavirus according to claim 1, wherein: the amino acid sequence of the heavy chain variable region of the monoclonal antibody is SEQ ID NO: 1, the amino acid sequence of the light chain variable region of the monoclonal antibody is SEQ ID NO: 5.
3. an isolated nucleic acid molecule, wherein: the nucleic acid molecule encodes the monoclonal antibody of any one of claims 1-2.
4. An expression vector comprising the nucleic acid molecule of claim 3.
5. A host cell comprising the nucleic acid molecule of claim 3 or the expression vector of claim 4.
6. A method for detecting the level of a new coronavirus, for non-diagnostic purposes, comprising: the method comprises the following steps:
extracting a sample containing new coronavirus;
contacting the sample obtained in the step I with the monoclonal antibody of any one of claims 1-2;
and thirdly, detecting the immunoreaction of the sample and the monoclonal antibody.
7. The use of the monoclonal antibody against non-RBD region of spinous process protein of a novel coronavirus according to any one of claims 1-2 for the preparation of a novel coronavirus detection product.
8. The use of the monoclonal antibody against non-RBD region of spinous process protein of neocoronavirus according to any one of claims 1-2 for the preparation of a medicament for inhibiting neocoronavirus.
9. The use of the monoclonal antibody against non-RBD region of spinous process protein of a novel coronavirus according to any one of claims 1-2 in the preparation of a pharmaceutical preparation for preventing or treating pneumonia caused by the novel coronavirus.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010414868 | 2020-05-15 | ||
CN2020104148681 | 2020-05-15 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111995676A true CN111995676A (en) | 2020-11-27 |
CN111995676B CN111995676B (en) | 2021-03-09 |
Family
ID=73392174
Family Applications (7)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010921453.3A Active CN111961133B (en) | 2020-05-15 | 2020-09-04 | Monoclonal antibody aiming at novel coronavirus SARS-CoV-2 spinous process protein non-RBD region and application thereof |
CN202010926531.9A Active CN111995676B (en) | 2020-05-15 | 2020-09-04 | Monoclonal antibody aiming at non-RBD (radial basis function) region of new coronavirus spike protein and application thereof |
CN202010926533.8A Active CN112010965B (en) | 2020-05-15 | 2020-09-04 | Monoclonal antibody aiming at new coronavirus SARS-CoV-2 spinous process protein RBD region and application thereof |
CN202010922039.4A Active CN111995675B (en) | 2020-05-15 | 2020-09-04 | Monoclonal antibody aiming at new coronavirus SARS-CoV-2 spinous process protein RBD region and application thereof |
CN202010926558.8A Active CN112010966B (en) | 2020-05-15 | 2020-09-04 | Monoclonal antibody aiming at non-RBD (radial basis function) region of new coronavirus spike protein and application thereof |
CN202010944546.8A Active CN111995677B (en) | 2020-05-15 | 2020-09-10 | Monoclonal antibody aiming at non-RBD (radial basis function) region of new coronavirus spike protein and application thereof |
CN202010944547.2A Active CN111995678B (en) | 2020-05-15 | 2020-09-10 | Monoclonal antibody aiming at new coronavirus SARS-CoV-2 spinous process protein RBD region and application thereof |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010921453.3A Active CN111961133B (en) | 2020-05-15 | 2020-09-04 | Monoclonal antibody aiming at novel coronavirus SARS-CoV-2 spinous process protein non-RBD region and application thereof |
Family Applications After (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010926533.8A Active CN112010965B (en) | 2020-05-15 | 2020-09-04 | Monoclonal antibody aiming at new coronavirus SARS-CoV-2 spinous process protein RBD region and application thereof |
CN202010922039.4A Active CN111995675B (en) | 2020-05-15 | 2020-09-04 | Monoclonal antibody aiming at new coronavirus SARS-CoV-2 spinous process protein RBD region and application thereof |
CN202010926558.8A Active CN112010966B (en) | 2020-05-15 | 2020-09-04 | Monoclonal antibody aiming at non-RBD (radial basis function) region of new coronavirus spike protein and application thereof |
CN202010944546.8A Active CN111995677B (en) | 2020-05-15 | 2020-09-10 | Monoclonal antibody aiming at non-RBD (radial basis function) region of new coronavirus spike protein and application thereof |
CN202010944547.2A Active CN111995678B (en) | 2020-05-15 | 2020-09-10 | Monoclonal antibody aiming at new coronavirus SARS-CoV-2 spinous process protein RBD region and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (7) | CN111961133B (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112940110A (en) * | 2021-04-14 | 2021-06-11 | 中山大学 | Anti-novel coronavirus N protein monoclonal antibody and application thereof |
CN113150135A (en) * | 2021-04-14 | 2021-07-23 | 中山大学 | Neutralizing antibodies against novel coronavirus receptor binding domains and uses thereof |
CN113501872A (en) * | 2021-06-22 | 2021-10-15 | 中国医学科学院病原生物学研究所 | Human source anti-novel coronavirus SARS-CoV-2 neutralizing antibody SK1 and application thereof |
CN114133447A (en) * | 2021-10-14 | 2022-03-04 | 河南晟明生物技术研究院有限公司 | Preparation method and application of 2019-nCoV surface protein receptor binding region antibody |
CN114702578A (en) * | 2022-06-06 | 2022-07-05 | 百斯医学诊断科技(北京)有限公司 | Novel coronavirus Omicron mutant strain specific antibody and application thereof |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113766928A (en) | 2020-04-02 | 2021-12-07 | 瑞泽恩制药公司 | anti-SARS-COV-2 fiber process glycoprotein antibody and antigen binding fragment |
BR112022024662A2 (en) | 2020-06-03 | 2023-04-04 | Regeneron Pharma | METHODS FOR TREATMENT OR PREVENTION OF SARS-COV-2 AND COVID-19 INFECTIONS WITH ANTI-SARS-COV-2 SPIKE GLYCOPROTEIN ANTIBODIES |
CN117003862B (en) * | 2020-08-19 | 2024-08-20 | 重庆医科大学 | New coronavirus RBD specific monoclonal antibody and application |
CN114989293B (en) * | 2020-08-19 | 2023-10-17 | 重庆医科大学 | New coronavirus RBD specific monoclonal antibody and application |
CN112062840A (en) | 2020-09-22 | 2020-12-11 | 石河子大学 | Nano antibody based on novel coronavirus S protein and application thereof |
WO2022068847A1 (en) * | 2020-09-29 | 2022-04-07 | 山东博安生物技术股份有限公司 | Method for treating or preventing diseases caused by novel coronavirus sars-cov-2 |
CN112409479B (en) * | 2020-11-23 | 2022-04-26 | 中国疾病预防控制中心病毒病预防控制所 | Humanized anti-neocoronavirus neutralizing antibody nCoV-121 and application thereof |
CN118344470A (en) * | 2020-12-02 | 2024-07-16 | 深圳先进技术研究院 | Broad-spectrum anti-coronavirus fully human monoclonal antibody and preparation method and application thereof |
CN112574300B (en) * | 2020-12-02 | 2022-03-08 | 深圳先进技术研究院 | anti-SAR-COV-2 fully human monoclonal antibody and preparation method and application thereof |
CN114605527B (en) * | 2020-12-04 | 2023-07-04 | 中国科学院分子细胞科学卓越创新中心 | Antibody for resisting novel coronavirus SARS-CoV-2 and its preparation method and use |
CN112611868A (en) * | 2020-12-18 | 2021-04-06 | 厦门大学 | Probe for detecting novel coronavirus by magnetic resonance analysis method and preparation method thereof |
CN114685653B (en) * | 2020-12-31 | 2023-09-12 | 中国科学院分子细胞科学卓越创新中心 | Neutralizing antibodies against epitopes of novel coronavirus receptor binding region and uses thereof |
US11834493B2 (en) * | 2021-01-05 | 2023-12-05 | Immunome, Inc. | Antibody cocktail against SARS-CoV-2 spike protein |
CN114716541B (en) * | 2021-01-05 | 2023-07-21 | 中国科学院分子细胞科学卓越创新中心 | Fully human broad spectrum neutralizing antibody 76E1 against coronavirus and application thereof |
CN112394180A (en) * | 2021-01-19 | 2021-02-23 | 南京立顶医疗科技有限公司 | Detection method and detection kit for SARS-CoV-2 neutralizing antibody |
CN113150129B (en) * | 2021-01-28 | 2023-02-28 | 四川大学华西医院 | Single-chain antibody for resisting S2 protein on surface of new coronavirus SARS-CoV-2 and application thereof |
CN112521496B (en) * | 2021-01-29 | 2022-09-06 | 中国人民解放军空军军医大学 | Monoclonal antibody specifically binding SARS-CoV-2 Spike RBD and application thereof |
CN114805556A (en) * | 2021-01-29 | 2022-07-29 | 中国科学院上海巴斯德研究所 | Neutralizing antibody for SARS-CoV-2 virus |
CN113150130B (en) * | 2021-01-31 | 2022-10-18 | 中南大学湘雅医院 | Novel coronavirus monoclonal antibody and application thereof |
CN115427432A (en) * | 2021-02-10 | 2022-12-02 | 斯微(上海)生物科技股份有限公司 | Vaccine agent for treating or preventing coronavirus disease mutant strain |
CN113009154B (en) * | 2021-02-25 | 2024-01-30 | 山东莱博生物科技有限公司 | Novel one-step method coronavirus neutralizing antibody magnetic microsphere detection kit and application thereof |
WO2022241415A1 (en) * | 2021-05-11 | 2022-11-17 | Yale University | Methods for monoclonal antibody generation |
WO2022241200A1 (en) * | 2021-05-14 | 2022-11-17 | Vanderbilt University | Cross-reactive coronavirus antibodies |
CN113307866B (en) * | 2021-05-26 | 2022-11-11 | 中山大学 | Antibody composition and application thereof |
CN113402603B (en) * | 2021-06-09 | 2022-05-03 | 陕西理工大学 | Avian single-chain antibody for resisting SARS-CoV-2 virus S1 protein and its application |
CN113416245A (en) * | 2021-06-15 | 2021-09-21 | 北京华大蛋白质研发中心有限公司 | Neutralizing antibody capable of combining SARS-CoV-2 virus RBD protein and application thereof |
CN113563483B (en) * | 2021-08-09 | 2024-02-02 | 广州明药科技有限公司 | Phage display novel coronavirus capsid protein and application |
CN113603786B (en) * | 2021-08-26 | 2023-05-30 | 深圳市亚辉龙生物科技股份有限公司 | Bispecific antibodies that specifically bind SARS-CoV-2S protein and N protein |
CN113929772B (en) * | 2021-09-30 | 2022-03-25 | 北京康乐卫士生物技术股份有限公司 | SARS-CoV-2 neutralizing antibody and its preparation method and use |
WO2023072904A1 (en) * | 2021-10-26 | 2023-05-04 | F. Hoffmann-La Roche Ag | Monoclonal antibodies specific for sars-cov-2 rbd |
CN114989291B (en) * | 2021-11-25 | 2023-01-06 | 浙江安维珞诊断技术有限公司 | RBD-targeted anti-SARS-CoV-2 fully humanized monoclonal antibody and application thereof |
CN116925177A (en) * | 2021-12-06 | 2023-10-24 | 浙江大学 | Novel affinity polypeptide of coronavirus spike protein receptor binding region RBD and application thereof |
CN113999301B (en) * | 2021-12-07 | 2023-07-28 | 江苏中新医药有限公司 | anti-SARS-CoV-2 (COVID-19) S protein RBD monoclonal antibody |
CN114106164B (en) * | 2021-12-09 | 2023-05-26 | 杭州旭科生物技术有限公司 | Monoclonal antibody for resisting novel coronavirus S protein and application thereof |
WO2023125964A1 (en) * | 2022-01-03 | 2023-07-06 | Versitech Limited | Neutralizing antibodies against covid-19 and methods of use thereof |
CN116041494B (en) * | 2022-12-12 | 2024-08-20 | 首都医科大学 | Monoclonal antibody for SARS-CoV or SARS-CoV-2, its preparation method and application |
CN115894675B (en) * | 2023-02-03 | 2023-11-14 | 康复大学(筹) | New coronavirus SARS-CoV-2 nucleocapsid protein monoclonal antibody and its application |
CN117551191A (en) * | 2023-11-15 | 2024-02-13 | 江苏省疾病预防控制中心(江苏省公共卫生研究院) | Monoclonal antibodies against SARS-CoV-2 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111592594A (en) * | 2020-03-13 | 2020-08-28 | 北京大学 | Monoclonal antibody for resisting novel coronavirus and application thereof |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2533113A1 (en) * | 2003-07-21 | 2005-02-03 | Government Of The United States Of America As Represented By The Secreta Ry Of The Department Of Health And Human Services National Institutes Of | Soluble fragments of the sars-cov spike glycoprotein |
MX2007009512A (en) * | 2005-02-08 | 2008-02-21 | New York Blood Ct Inc | Neutralizing monoclonal antibodies against severe acute respiratory syndrome-associated coronavirus. |
EP2242768A4 (en) * | 2008-01-17 | 2012-03-14 | Humabs Llc | Cross-neutralizing human monoclonal antibodies to sars-cov and methods of use thereof |
CN111157723B (en) * | 2020-02-16 | 2023-07-04 | 广西中医药大学附属瑞康医院 | Novel coronavirus rapid detection box |
CN110951756B (en) * | 2020-02-23 | 2020-08-04 | 广州恩宝生物医药科技有限公司 | Nucleic acid sequence for expressing SARS-CoV-2 virus antigen peptide and its application |
CN111122879B (en) * | 2020-03-26 | 2020-07-14 | 珠海丽珠试剂股份有限公司 | Coating liquid of novel coronavirus recombinant antigen, pretreatment method, application and product |
CN111690059B (en) * | 2020-06-19 | 2022-03-08 | 武汉生物制品研究所有限责任公司 | Monoclonal antibody 1D7 for resisting SARS-CoV-2 |
CN111995672B (en) * | 2020-07-20 | 2022-05-20 | 江苏集萃医学免疫技术研究所有限公司 | Specific antibody of coronavirus SARS-COV-2S protein and its use |
CN115477698A (en) * | 2020-08-19 | 2022-12-16 | 重庆医科大学 | New coronavirus RBD specific monoclonal antibody and application |
-
2020
- 2020-09-04 CN CN202010921453.3A patent/CN111961133B/en active Active
- 2020-09-04 CN CN202010926531.9A patent/CN111995676B/en active Active
- 2020-09-04 CN CN202010926533.8A patent/CN112010965B/en active Active
- 2020-09-04 CN CN202010922039.4A patent/CN111995675B/en active Active
- 2020-09-04 CN CN202010926558.8A patent/CN112010966B/en active Active
- 2020-09-10 CN CN202010944546.8A patent/CN111995677B/en active Active
- 2020-09-10 CN CN202010944547.2A patent/CN111995678B/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111592594A (en) * | 2020-03-13 | 2020-08-28 | 北京大学 | Monoclonal antibody for resisting novel coronavirus and application thereof |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112940110A (en) * | 2021-04-14 | 2021-06-11 | 中山大学 | Anti-novel coronavirus N protein monoclonal antibody and application thereof |
CN113150135A (en) * | 2021-04-14 | 2021-07-23 | 中山大学 | Neutralizing antibodies against novel coronavirus receptor binding domains and uses thereof |
CN113150135B (en) * | 2021-04-14 | 2022-09-20 | 中山大学 | Neutralizing antibodies against novel coronavirus receptor binding domains and uses thereof |
CN112940110B (en) * | 2021-04-14 | 2022-09-20 | 中山大学 | Anti-novel coronavirus N protein monoclonal antibody and application thereof |
CN113501872A (en) * | 2021-06-22 | 2021-10-15 | 中国医学科学院病原生物学研究所 | Human source anti-novel coronavirus SARS-CoV-2 neutralizing antibody SK1 and application thereof |
CN113501872B (en) * | 2021-06-22 | 2022-05-24 | 中国医学科学院病原生物学研究所 | Human source anti-novel coronavirus SARS-CoV-2 neutralizing antibody SK1 and application thereof |
CN114133447A (en) * | 2021-10-14 | 2022-03-04 | 河南晟明生物技术研究院有限公司 | Preparation method and application of 2019-nCoV surface protein receptor binding region antibody |
CN114133447B (en) * | 2021-10-14 | 2022-07-19 | 河南晟明生物技术研究院有限公司 | Preparation method and application of 2019-nCoV surface protein receptor binding region antibody |
CN114702578A (en) * | 2022-06-06 | 2022-07-05 | 百斯医学诊断科技(北京)有限公司 | Novel coronavirus Omicron mutant strain specific antibody and application thereof |
CN114702578B (en) * | 2022-06-06 | 2022-09-27 | 百斯医学诊断科技(北京)有限公司 | Novel coronavirus Omicron mutant strain specific antibody and application thereof |
Also Published As
Publication number | Publication date |
---|---|
CN111961133A (en) | 2020-11-20 |
CN112010965B (en) | 2021-03-12 |
CN111995677A (en) | 2020-11-27 |
CN112010966A (en) | 2020-12-01 |
CN111995675B (en) | 2021-03-23 |
CN112010965A (en) | 2020-12-01 |
CN111995675A (en) | 2020-11-27 |
CN111961133B (en) | 2021-03-23 |
CN111995678A (en) | 2020-11-27 |
CN111995678B (en) | 2021-03-09 |
CN111995676B (en) | 2021-03-09 |
CN111995677B (en) | 2021-03-23 |
CN112010966B (en) | 2021-03-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111995676B (en) | Monoclonal antibody aiming at non-RBD (radial basis function) region of new coronavirus spike protein and application thereof | |
CN113429478B (en) | Monoclonal antibody H9 against novel coronavirus SARS-CoV-2 | |
US11820811B2 (en) | Nano-antibody and its application based on SARS-CoV-2 S protein | |
CN108017712B (en) | Protein skeleton derived from shark antibody and application thereof | |
CN114478696B (en) | Novel affinity polypeptide of coronavirus spike protein receptor binding region RBD and application thereof | |
WO2022061594A1 (en) | Sars-cov-2 spike protein binding molecule and use thereof | |
WO2023216623A1 (en) | CAMEL-DERIVED HIGH-AFFINITY NANOANTIBODY AGAINST SARS-COV-2 α, γ, δ AND ο MUTANTS | |
KR20210035249A (en) | NS1 protein binding protein | |
Chen et al. | Synthetic antibodies and peptides recognizing progressive multifocal leukoencephalopathy-specific point mutations in polyomavirus JC capsid viral protein 1 | |
CN114773459B (en) | Nano antibody for resisting novel coronavirus and variant thereof, preparation method and application thereof | |
US20240117012A1 (en) | Anti-sars-cov-2 antibody | |
CN110903385B (en) | H1N1 influenza virus antibody and preparation method and application thereof | |
CN113980127A (en) | Nano antibody for resisting methicillin-resistant staphylococcus and preparation method and application thereof | |
CN107793471B (en) | Folate receptor alpha specific binding peptide 4 and application thereof | |
CN107446021B (en) | Folate receptor alpha specific binding peptide 5 and application thereof | |
CN110845607B (en) | H1N1 influenza virus antibody and application thereof in H1N1 virus ultramicro-detection | |
CN107513099A (en) | A kind of polystyrene affinity peptide and its method for improving antigen fixed effect | |
CN113943367B (en) | Single domain antibodies against novel coronaviruses, kits and medicaments | |
KR102266878B1 (en) | Potato leafroll virus Specific Antibody from Human Scfv Antibody Phage Display Library and Uses thereof | |
Zhao et al. | A high potent synthetic nanobody with broad-spectrum activity neutralizes SARS-Cov-2 virus and Omicron variant through a unique binding mode | |
Johansson | Proteomic peptide phage display of syntenin-1 and scribble | |
CN115124616A (en) | Nano antibody with specificity aiming at SARS-CoV-2RBD | |
Mamunur Rahman et al. | New avenues for phage‐display library to produce a Cryptococcus‐specific anti‐idiotypic antibody of HM‐1 killer toxin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |